BLTE Stock Analysis: Belite Bio | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.878m USD | 12M Return: 169% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.2M
Warnings
Tailwinds
Seasonality 4.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Belite Bio, Inc. (NASDAQ: BLTE) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California. It operates as a subsidiary of Lin Bioscience International Ltd. and went public via IPO on April 29, 2022. As a pre-revenue biotech, the companys business model is centered on advancing a small pipeline of internally developed drug candidates through clinical milestones to attract development partners or pursue commercialization, with operations funded by capital markets rather than product sales.
The companys lead candidate, Tinlarebant (LBS-008), is an orally administered small molecule currently in Phase 3 clinical development. It is being evaluated for the treatment of Stargardt disease type 1 (STGD1) and geographic atrophy (GA), both progressive retinal degenerative diseases that are leading causes of irreversible vision loss and currently have no approved disease-modifying therapies.
Belite is also advancing LBS-009, an oral retinol binding protein 4 (RBP4) inhibitor in preclinical development. The program targets metabolic and inflammatory conditions including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes, and gout-therapeutic areas characterized by large patient populations and high unmet medical need that have drawn significant R&D investment across the biotechnology sector.
- Tinlarebant Phase 3 Stargardt disease data readout
- Cash burn rises as Phase 3 enrollment expands
- GA competition intensifies with Syfovre and Izervay approvals
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 13.31 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.05 > 3% & CFO -37.0m > Net Income -90.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 52.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.9m) vs 12m ago 24.26% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -50.7k > 6 (EBIT TTM -101.4m / Interest Expense TTM 2.00k) |
| A: 0.63 (Total Current Assets 521.9m - Total Current Liabilities 9.88m) / Total Assets 811.3m |
| B: -0.23 (Retained Earnings -185.3m / Total Assets 811.3m) |
| C: -0.21 (EBIT TTM -101.4m / Avg Total Assets 487.7m) |
| D: 51.40 (Book Value of Equity 795.8m / Total Liabilities 15.5m) |
| Altman-Z'' = 55.97 = AAA |
As of July 08, 2026, the stock is trading at USD 157.69 with a total of 222,510 shares traded. Over the past week, the price has changed by +1.97%, over one month by +12.93%, over three months by -7.13% and over the past year by +168.96%.
Current recommended Stop Loss: 139.20 (which is 11.7% or 2.3 ATR below the current price).
Belite Bio has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy BLTE.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 210.5 | 33.5% |
P/E Forward = 227.2727
P/B = 7.386
Revenue TTM = 0.0 USD
EBIT TTM = -101.4m USD
EBITDA TTM = -100.9m USD
Long Term Debt = unknown (none)
Short Term Debt = 241k USD (from shortTermDebt, last fiscal year)
Debt = 429k USD (from shortLongTermDebtTotal, last fiscal year) (leases 429k already included)
Net Debt = -492.0m USD (calculated: Debt 429k - CCE 492.4m)
Enterprise Value = 5.39b USD (5.88b + Debt 429k - CCE 492.4m)
Interest Coverage Ratio = -50.7k (Ebit TTM -101.4m / Interest Expense TTM 2.00k)
EV/FCF = -144.9x (Enterprise Value 5.39b / FCF TTM -37.2m)
FCF Yield = -0.69% (FCF TTM -37.2m / Enterprise Value 5.39b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 6.64 (Enterprise Value 5.39b / Total Assets 811.3m)
Interest Expense / Debt = 0.47% (Interest Expense 2.00k / Debt 429k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -80.1m (EBIT -101.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 52.81 (Total Current Assets 521.9m / Total Current Liabilities 9.88m)
Debt / Equity = 0.00 (Debt 429k / totalStockholderEquity, last quarter 795.8m)
Debt / EBITDA = 4.88 (negative EBITDA) (Net Debt -492.0m / EBITDA -100.9m)
Debt / FCF = 13.24 (negative FCF - burning cash) (Net Debt -492.0m / FCF TTM -37.2m)
Total Stockholder Equity = 497.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.51% (Net Income -90.3m / Total Assets 811.3m)
RoE = -18.14% (Net Income TTM -90.3m / Total Stockholder Equity 497.6m)
RoCE = -12.65% (EBIT -101.4m / Capital Employed (Total Assets 811.3m - Current Liab 9.88m))
RoIC = -9.99% (negative operating profit) (NOPAT -80.1m / Invested Capital 801.6m)
WACC = 6.99% (E(5.88b)/V(5.88b) * Re(6.99%) + D(429k)/V(5.88b) * Rd(0.47%) * (1-Tc(0.21)))
Discount Rate = 6.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 16.42%
[DCF] Fair Price = unknown (Cash Flow -37.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.34 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.77 | Chg30d=-15.36% | Revisions=-10% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.82 | Chg30d=-19.16% | Revisions=-10% | Analysts=7
EPS current Year (2026-12-31): EPS=-3.28 | Chg30d=-54.19% | Revisions=-30% | GrowthEPS=-42.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=+20.29% | Revisions=-22% | GrowthEPS=+128.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -23% (up=10, down=17)